Byrd JC - Search Results

1

Dinaciclib is a novel cyclin-dependent kinase inhibitor with significant clinical activity in relapsed and refractory chronic lymphocytic leukemia.

Flynn J, Jones J, Johnson AJ, Andritsos L, Maddocks K, Jaglowski S, Hessler J, Grever MR, Im E, Zhou H, Zhu Y, Zhang D, Small K, Bannerji R, Byrd JC. Flynn J, et al. Among authors: byrd jc. Leukemia. 2015 Jul;29(7):1524-9. doi: 10.1038/leu.2015.31. Epub 2015 Feb 24. Leukemia. 2015. PMID: 25708835 Free PMC article. Clinical Trial.

2

Introduction: chronic lymphocytic leukemia.

Byrd JC, Flinn IW, Grever MR. Byrd JC, et al. Semin Oncol. 1998 Feb;25(1):4-5. Semin Oncol. 1998. PMID: 9482520 No abstract available.

3

Old and new therapies in chronic lymphocytic leukemia: now is the time for a reassessment of therapeutic goals.

Byrd JC, Rai KR, Sausville EA, Grever MR. Byrd JC, et al. Semin Oncol. 1998 Feb;25(1):65-74. Semin Oncol. 1998. PMID: 9482528 Review.

4

Flavopiridol induces apoptosis in chronic lymphocytic leukemia cells via activation of caspase-3 without evidence of bcl-2 modulation or dependence on functional p53.

Byrd JC, Shinn C, Waselenko JK, Fuchs EJ, Lehman TA, Nguyen PL, Flinn IW, Diehl LF, Sausville E, Grever MR. Byrd JC, et al. Blood. 1998 Nov 15;92(10):3804-16. Blood. 1998. PMID: 9808574 Free article.

5

Stem-cell transplantation in chronic lymphocytic leukemia: the time for designing randomized studies has arrived.

Waselenko JK, Flynn JM, Byrd JC. Waselenko JK, et al. Among authors: byrd jc. Semin Oncol. 1999 Feb;26(1):48-61. Semin Oncol. 1999. PMID: 10073561 Review.

6

Depsipeptide (FR901228): a novel therapeutic agent with selective, in vitro activity against human B-cell chronic lymphocytic leukemia cells.

Byrd JC, Shinn C, Ravi R, Willis CR, Waselenko JK, Flinn IW, Dawson NA, Grever MR. Byrd JC, et al. Blood. 1999 Aug 15;94(4):1401-8. Blood. 1999. PMID: 10438728 Free article.

7

Update on the biology of chronic lymphocytic leukemia.

Bannerji R, Byrd JC. Bannerji R, et al. Among authors: byrd jc. Curr Opin Oncol. 2000 Jan;12(1):22-9. doi: 10.1097/00001622-200001000-00004. Curr Opin Oncol. 2000. PMID: 10687725 Review.

8

Theophylline, pentostatin (Nipent), and chlorambucil: a dose-escalation study targeting intrinsic biologic resistance mechanisms in patients with relapsed lymphoproliferative disorders.

Byrd JC, Grever MR, Waselenko JK, Willis CR, Park K, Goodrich A, Lucas MA, Shinn C, Flinn IW. Byrd JC, et al. Semin Oncol. 2000 Apr;27(2 Suppl 5):37-40. Semin Oncol. 2000. PMID: 10877050

9

Pentostatin (Nipent) and chlorambucil with granulocyte-macrophage colony-stimulating factor support for patients with previously untreated, treated, and fludarabine-refractory B-cell chronic lymphocytic leukemia.

Waselenko JK, Grever MR, Beer M, Lucas MA, Byrd JC. Waselenko JK, et al. Among authors: byrd jc. Semin Oncol. 2000 Apr;27(2 Suppl 5):44-51. Semin Oncol. 2000. PMID: 10877052 Review.

10

Fludarabine and cyclophosphamide with filgrastim support in patients with previously untreated indolent lymphoid malignancies.

Flinn IW, Byrd JC, Morrison C, Jamison J, Diehl LF, Murphy T, Piantadosi S, Seifter E, Ambinder RF, Vogelsang G, Grever MR. Flinn IW, et al. Among authors: byrd jc. Blood. 2000 Jul 1;96(1):71-5. Blood. 2000. PMID: 10891432 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

861 results

Search Page

Filters